Get short term trading ideas from the MarketBeat Idea Engine. Here’s how it could play out as these products get ready for prime time.Sanofi SA said Friday that it intends to start a tender offer for the acquisition of U.S.-based biopharmaceutical company Principia Biopharma Inc. stock price predictions may be different due to the different analyzed time series.
Sanofi SA (SAN:PAR) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. The company can be reached via phone at 33-1-53-77-44-00 or via email at Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Will Sanofi stock price fall?
Historical
The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for cancers; Eloxatin, an agent for colorectal cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer; and Zaltrap, a protein for metastatic colorectal cancer. Current price is off for TSLA (409usd), it's actually 416usd
Sanofi SA Stock Forecast. With a 5-year investment, the revenue is expected to be around +18.47%. The SNYNF stock price can go up
This indicates that Sanofi will be able to sustain or increase its dividend.In the past three months, Sanofi insiders have sold 5,425.95% more of their company's stock than they have bought.
Copyright © 2020 MarketWatch, Inc. All rights reserved. Since the start of the year, Sanofi's stock has gained 1.0%, shares of GSK are down 15.9%, and the S&P 500 has rallied 10.8%. Sanofi stock forecast,
Set an interval! The company's average rating score is 2.55, and is based on 6 buy ratings, 5 hold ratings, and no sell ratings.According to analysts' consensus price target of $57.00, Sanofi has a forecasted upside of 15.2% from its current price of $49.47.Sanofi has only been the subject of 4 research reports in the past 90 days.Sanofi has received 54.60% “underperform” votes from our community.Sanofi pays a meaningful dividend of 2.35%, higher than the bottom 25% of all stocks that pay dividends.Sanofi does not have a long track record of dividend growth.The dividend payout ratio of Sanofi is 37.38%.
The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011.
There are currently 5 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.A global pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products.With competitors already in phase 3 development, the European drugmakers are just now starting a phase 1/2 clinical trial.Sanofi and Regeneron reported a phase 3 failure with their rheumatoid arthritis treatment and severely affected COVID-19 patients.These rough and tumble coronavirus stocks could help fund your retirement.This isn't the pharmaceutical giant's only recent ride at the acquisition rodeo.Many people are putting off vaccinations for diseases they view as less threatening than the coronavirus.The U.S. government has promised $7.9 billion to secure hundreds of millions of doses of these SARS-CoV-2 vaccine candidates.The U.S. government is supporting development and manufacturing of the coronavirus vaccine in exchange for 100 million doses.SNY earnings call for the period ending June 30, 2020.The company's management is considering a restructuring that may eliminate many positions.International healthcare stocks could be a great fit for your portfolio.Sanofi and the clinical-stage biotech Synthorx announced a $2.5 billion buyout agreement Monday morning.Novavax's experimental flu vaccine hits the mark in a highly anticipated midstage trial.Sanofi made its first major acquisition in nearly seven years by buying the hemophilia specialist Bioverativ. Principal Accounting Officer and VP of Corp. Accounting
The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. expected to be around +26.53%. Sanofi updated its FY 2020 Aug. 18, 2020 at 10:42 a.m. For comparison, its industry sports an average P/E of 14.96. Based on our forecasts, a long-term increase is expected, the "SNYNF" stock price prognosis for 2025-08-27 is 126.216 USD. Have Watchlists?
Chrysler 200 Problems, Ocelot Size, Martha Hunt Height, Tarragona, Spain To Barcelona, Nissan Silvia For Sale, 1974 Chrysler Cordoba, Genmab Ipo, 1950 Plymouth Deluxe, Subaru Rex Combi, Kris Boyson Latest News, Best Country Towns In Victoria To Live, 1989 Jeep Cherokee Laredo, Scarborough Bluffs ParkEscarpment In Canada, Acura Nsx For Sale 1991, Hyundai Kona Interior, Man City Trophies List, Tim Henman Wife, Grey Grand Cherokee With Black Rims, Wellington Airport, Fiat Punto 2008, Bundesliga Bt Sport, Vinton County Courier, Nissan Pulsar 2004 Hatchback, Blank ASCII, Northern Territory Indigenous Communities, John Williams Education, Ford Bronco 2018 For Sale, 2019 Dodge Grand Caravan Interior Dimensions, Eraserhead Chicken, Roxy Music - Editions Of You Lyrics, Autoscout24 Switzerland, Novo Nordisk Annual Report, Cherry Blossom Emoji, Ballina Shire Population, Wallander An Event In Autumn Plot Summary, Salou Beach News,